UNIVERSITY OF CALIFORNIA SAN FRANCISCO

Dr. Okada’s lab is researching a new form of immunotherapy treatment for pediatric brain tumors, including pediatric DIPG, a devastating type of brain tumor that has a median survival rate of less than one year. Dr. Okada’s research involves adoptive transfer therapy, in which a patients’ T-cell lymphocytes are removed, genetically engineered and re-infused to target specific antigens.